Network Italiano per la Bioterapia dei Tumori
One post-doctoral position, sponsored by the Italian Association for Cancer Research (AIRC), is immediately available in the Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases,
at the San Raffaele Scientific Institute, Milan, Italy.
The position is offered to investigate the molecular basis of the interactions between the microbiota and the
immune system driving multiple myeloma aggressiveness. The interested candidate can check our recent
publications in this area to get more insights on the project:
• Bellone M, et al. Microbiol Mol Biol Rev 2020 (doi: 10.1128/MMBR.00064-19)
• Calcinotto A, Brevi A, et al. Nat Commun 2018 (doi: 10.1038/s41467-018-07305-8)
• Calcinotto A, et al., OncoImmunology 2015 (PMID: 26155424)
The successful applicant will participate in a work team that combines high-dimensional multicolor flow
cytometry, metagenomics, and genetically engineered mouse models to unveil immunological changes
across the gut-bone marrow networks in both humans and preclinical models of multiple myeloma.
Ambitious, and self-motivated ideal candidates for the position with relevant education or experience in
immunology are invited to apply, though preference will be given to candidates with experience in flow
cytometry. Demonstration of excellent teamwork and collaborative skills will be highly desirable. Please send
your curriculum vitae, a brief description of research interests and career goals, and contact information for
two references to Dr. Matteo Bellone, via email at: Bellone.email@example.com
The San Raffaele Scientific Institute is a private organization that includes a research hospital recognized by
the Italian Ministry of Health, a research institute and the associated Vita-Salute San Raffaele University.
Integrated clinical, research and training activities are conducted with > 1,300 beds, around 1,600 basic,
clinical and translational scientists, and almost 3000 students. A common campus hosts all teaching, basic,
translational and clinical research activities in a large infrastructural compound. Hence, the San Raffaele
offers the opportunity to work in a unique environment where basic, translational and clinical research Units,
hospital Departments and teaching activities effectively interact on a daily basis. Mission of the San Raffaele
Scientific Institute is to advance the knowledge on human diseases, and to identify novel therapies through
basic and translational research. More information can be found at:
We are looking for an outstanding and highly motivated Scientist to work on the AIRC-funded research project (from February 2021):
“Targeting IL-10 producing regulatory T-cells in cancer”
The ideal successful candidate should have experience with mouse cancer models, lymphocyte culture (both human and murine),
flow cytometry and molecular biology techniques. The ideal candidate also should be available to work part of the time
in Italy (Milan) and in Bellinzona (Switzerland).
Häringer et al., J Exp Med 2009
Geginat et al., Cyt Growth Fact Rev 2016
Alfen et al., J Allergy Clin Immunol 2018
J Geginat (Editorial), Semin Immunol 2019
Gruarin et al., Eur J Immunol 2019
Please send your CV to Jens Geginat firstname.lastname@example.org - https://ingm.org/en/geginat_lab_eng
ISTITUTO NAZIONALE GENETICA MOLECOLARE “Romeo ed Enrica Invernizzi”
Via Francesco Sforza, 35 – 20122 Milano, Italia
Tel. +39 02 0066 0211– Fax +39 02 0066 0216 – E-mail: email@example.com
Codice Fiscale 04175700964
A research position is immediately available in the laboratory of Dr. Maria Pia Protti at the
Tumor Immunology Unit, Division of Immunology, San Raffaele Scientific Institute of Milan.
The major interest in the laboratory is the study of the tumor microenvironment, and in
particular of the immune cell infiltrates with anti- versus pro-tumor functions with special
emphasis on the role of T helper (Th) cells.
In the last years we focused on pancreatic ductal adenocarcinoma and we identified a tumorpromoting
function for tumor infiltrating Th2 cells that depends on a complex cross-talk
between tumor cells, cancer associated fibroblasts and immune cells, within the tumor
microenvironment and tumor draining lymph nodes, among which monocytes, tumor
associated macrophages, dendritic cells, T cells and basophils (De Monte L et al., J Exp Med
2011; 208:469; De Monte L et al., Cancer Res 76:1792). Cytokines and soluble factors key to
the development of Th2 inflammation were also identified, and specifically tumor-derived IL-
1 and cancer associated fibroblast-derived thymic stromal lymphopoietin (TSLP) (Brunetto E,
De Monte L et al., J Immunother Cancer 2019;7:45). Targeting of these molecules might
impact on the immunosuppressive tumor microenvironment by repolarizing the immune
contexture towards anti-tumor Th1 inflammation.
The candidate will be involved in the study of mechanisms of immunosuppression in the
pancreatic cancer microenvironment, and of development of therapeutic strategies targeting
molecules/cytokines of interest. These studies are conducted in the framework of an
international EURONANOMED program testing in vitro and in vivo targeting strategies based
on the delivery of therapeutics by nanoparticles. Specifically, the efficacy of blocking IL-1
availability in the tumor microenvironment using the IL-1R antagonist molecule incorporated
in nanoparticles will be first tested.
We are looking for a highly motivated candidate (either a junior or post-doctoral fellow) with
strong interest in immunology, and experience in cellular immunology and basic molecular
biology. Experience in fluorescence and confocal microscopy would be considered a plus.
Interested candidates should send their CVs, a brief statement of research and career interest,
and at least one contact information for references to: firstname.lastname@example.org
with proved experience in the field of human T cell immunobiology and T cellengineering.
The position is initially limited to three years with the possibility to be continued and is remunerated on the TV-L salary scale (TV-L EG 14)
The RCI - Regensburg Center for Interventional Immunology (foundation under public law) is a novel biomedical research center focusing on translational immunology in the
fields of cancer immunotherapy, transplant rejection and autoimmunity. The objective of the RCI is to develop effective immune therapeutic strategies in these areas.
The senior scientist will be responsible for the development of clinical-grade protocols
for the manufacturing of gene-engineered T cells that will be employed in Phase 1/2
clinical studies at the University Hospital Regensburg. Projects derive from recent basic
research and translational pre-clinical studies conducted at the RCI and primarily within
the Department of Functional Immune Cell Modulation. Gene manipulations encompass
the modulation of transcription factors, microRNAs and metabolic checkpoints coupled
with CAR and TCR platforms to functionally improve the antitumor efficacy of generedirected
Responsibilities include, but are not limited to:
• Perform all tasks associated with the manufacturing of clinical-grade cell
products including the development of standard operating procedures (SOPs),
batch records and other GMP documentation.
• Design and conduct clinical assays required to support assessment of T cell
• Successfully troubleshoot processing and equipment issues.
The ideal candidate possesses:
• PhD in Molecular Biology, Cell Biology, Immunology or a relevant discipline and
5 or more years of cGMP experience in a T cell manufacturing and biotechnology
• Extensive experience in isolating, culturing human T cells.
• Extensive experience with virus-based and nonviral gene delivery platforms.
• Experience with automated processing equipment.
• Strong knowledge of cGMP regulations and experience in writing SOPs and documentation associated with clinical-grade cell manufacturing.
• Excellent communications skills, both oral and written in English. •Strong analytical, organizational and time management skills.
The RCI follows the goal of professional equality for all genders and therefore strongly encourages qualified women to apply. In addition, the RCI supports work-family balance.
The RCI is an equal opportunity employer and candidates with disabilities will be given preference, provided they are equally qualified.
If we have awakened your interest and you are open to new professional challenges, we would be delighted to receive an informative application from you.
Please send your full application including a statement of interest, curriculum vitae, certificates, expected availability date, a list of publications and 2-3
references by e-mail to Prof. Dr. Philipp Beckhove (email@example.com). Application deadline is June 30, 2020.
RCI – Regensburger Centrum für Interventionelle Immunologie
c/o Universitätsklinikum Regensburg
For more information contact : Prof. Luca Gattinoni (e-mail: firstname.lastname@example.org phone: +49 941 944 38132)